PROVEN-DIA Trial: A New Approach to Prevent Type 2 Diabetes in Brazil

Type 2 diabetes (T2D) is a growing health crisis, affecting over 16 million Brazilians and having nearly doubled in prevalence over the past two decades. This alarming trend highlights the urgent need for effective prevention strategies, especially in middle-income countries like Brazil where lifestyle interventions have shown promise but lack large-scale validation. The PROVEN-DIA trial seeks to fill this gap by evaluating the effectiveness of a structured lifestyle intervention program delivered through both telehealth and hybrid formats. The PROVEN-DIA trial is a multicenter, open-label, randomized controlled superiority trial that will enroll 1,305 adults with prediabetes across 30 sites in Brazil. Participants will be randomly assigned to one of three groups: two intervention groups receiving a structured 36-month lifestyle program (PROVEN-DIA and TelePROVEN-DIA) and a control group receiving unstructured lifestyle guidance. The primary outcome of the trial is the cumulative incidence of type 2 diabetes at 36 months, while secondary outcomes include changes in body weight, fasting glucose, glycated hemoglobin (HbA1c), and various lifestyle factors such as dietary quality and physical activity. This trial has significant practical implications for individuals at risk of developing T2D. By participating in a structured program that emphasizes diet, physical activity, and other lifestyle factors, individuals may reduce their risk of progressing from prediabetes to diabetes. The trial's design allows for a comparison of the effectiveness of telehealth versus in-person support, potentially offering insights into how best to deliver diabetes prevention programs in resource-limited settings. Key biomarkers relevant to this study include fasting glucose and HbA1c, which are critical for assessing metabolic health and diabetes risk. Individuals can utilize Metabolicum's calculators to monitor these biomarkers and track their progress throughout the trial. Additionally, understanding the impact of lifestyle changes on these biomarkers can empower participants to make informed decisions about their health. In conclusion, the PROVEN-DIA trial represents a significant step forward in diabetes prevention research in Brazil. By addressing the challenges of delivering effective lifestyle interventions in diverse settings, this study could pave the way for scalable diabetes prevention programs that improve metabolic health outcomes for millions of individuals at risk of T2D.